Navigation Links
Savara Closes Series A Financing Round
Date:6/9/2009

- Funds Raised Will Be Used to Expand Technology into New Pulmonary Markets -

AUSTIN, Texas, June 9 /PRNewswire/ -- Savara Pharmaceuticals, a biotechnology inhalation drug delivery company, today announced that it has closed its Series A financing round.

The majority of Savara's existing investors participated in the round, which was made up of biotechnology industry veterans and successful business leaders. Savara will utilize the funds to continue development of its NanoCluster technology in the dry powder therapeutics market and expand into nebulizer and propellant markets.

"I'm excited that we exceeded our entire Series A fund raising goal in just a few weeks," said Rob Neville, Savara's Executive Chairman. "The funds from our seed round allowed us to validate our technology across multiple drug classes, which led to several partnerships with large pharmaceutical companies. We've assembled a world class team and are ready to pursue the numerous opportunities ahead of us."

Savara has the option to complete a second tranche of the Series A round later this year if additional funds are needed.

The key parameter to improving the efficacy of pulmonary products depends on being able to dial-in particles sizes in the range of one to three microns. The Savara NanoCluster technology has this capability without the need for novel excipients and benefits from a highly efficient manufacturing process. These NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung.

About Savara

Savara Pharmaceuticals, (www.savarapharma.com) develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster's unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara's NanoCluster technology is currently available for evaluation and licensing.

CONTACT: Ian M. Stone for Savara Pharmaceuticals, +1-619-528-2220, ian.stone@russopartnersllc.com


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $12.65 million Unit Offering
2. Swine Flu Closes Three Schools in NYC
3. Swine Flu Closes 3 Schools in NYC
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. ASA May Day - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter
6. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
7. PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer
8. ProAssurance Closes PICA Transaction
9. Conseco Closes Amendment to Credit Facility
10. ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
11. GetWellNetwork Closes $10 Million Financing, Eight Hospitals Choose PatientLife System(R) for Unparalleled Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable Allscripts ... and select appointments via Everseat’s free mobile app. , The partnership gives Everseat ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm ... 7:00pm – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , ...
(Date:2/10/2016)... ... ... Workrite Ergonomics, who is celebrating their 25th year of business in 2016, is ... recognized leader in their industry. , "We are very proud of our heritage and ... “Workrite recognized the importance of good ergonomics before most of our competition even knew ...
(Date:2/10/2016)... ... 2016 , ... Anxiety of older Americans over steep cost increases of prescription ... decade ago, according to The Senior Citizens League (TSCL). Since last ... with rapidly rising costs. “The implications are chilling, particularly for people with chronic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 ALSP, Inc. announced that it has appointed ... Medical Affairs in preparation for its move into clinical trials ... CEO, stated, "We are pleased to welcome Dallas Hack ... with an individual of such practical knowledge and far-reaching experience ... deeply on his broad experience and success as a clinician ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch Solutions, a ... identified an industry-wide trend regarding the evolution of ... organizations to efficiently deliver compelling sales presentations via ... and another in 2015, Intouch uncovered that while ... devices and DSAs, many are not using them ...
(Date:2/10/2016)... 2016  Until recently, the options for reducing the ... the FDA approved the non-invasive Coolsculpting treatment, which removes ... originally approved in 2010 for the abdomen and this ... chin. With this add-on approval, the experts at Laser ... applicator, the CoolMini, to address smaller areas of fat. ...
Breaking Medicine Technology: